Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease.
D000109:Acetylcholine / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D019069:Cell Respiration / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D042963:Electron Transport Complex II / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000633:toxicity; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006816:Huntington Disease / Q000201:enzymology* / Q000209:etiology / Q000503:physiopathology; D066298:In Vitro Techniques; D007395:Interneurons / Q000187:drug effects / Q000201:enzymology; D007424:Intracellular Fluid / Q000187:drug effects / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology*; D017072:Neostriatum / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology; D009410:Nerve Degeneration / Q000139:chemically induced / Q000201:enzymology* / Q000503:physiopathology; D009574:Nitro Compounds; D011422:Propionates / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D004791:Enzyme Inhibitors; D009574:Nitro Compounds; D011422:Propionates; D005680:gamma-Aminobutyric Acid; D000255:Adenosine Triphosphate; D042963:Electron Transport Complex II; D000109:Acetylcholine; C015392:3-nitropropionic acid